Abstract Purpose Factor Xa Inhibitors have emerged as a first-line agent in the management
of non-valvular atrial fibrillation (NVAF), but there is a need for additional data surrounding …

Background Apixaban and rivaroxaban are increasingly used for thromboembolism
prophylaxis in patients with non‐valvular atrial fibrillation (NVAF) and commonly in patients …

Background Because studies of direct oral anticoagulants in patients with venous
thromboembolism and non-valvular atrial fibrillation have had minimal representation of …

Background: Contemporary guidelines for managing nonvalvular atrial fibrillation (NVAF)
include apixaban and rivaroxaban as first-line anticoagulation treatment options. Minimal …

Introduction Atrial fibrillation (AF) is the most common arrhythmia, with an estimated
prevalence between 1–4%. On the other hand, obesity continued to be a prevalent health …

Background Atrial fibrillation (AF) is an irregular heart rhythm which is becoming more and
more common in this new era. Obesity is a risk factor for cardiovascular events, and obese …

Background: Direct oral anticoagulants (DOACs) have been increasingly preferred over
warfarin; however, The International Society of Thrombosis and Hemostasis recommended …

Introduction: Obese and morbidly obese patients are under-represented in clinical trials of
non-vitamin K oral anticoagulants (NOAC). Patients with atrial fibrillation (AF) and …

To our knowledge, this is the first NMA study comparing apixaban with rivaroxaban in
morbidly obese patients with AF. Our NMA showed there was no significant difference in …

Background and aim Atrial fibrillation (AF) is the most frequently observed cardiac
arrhythmia in clinical settings. Obesity can influence the efficacy of the treatment …